Affiliation:
1. Department of Internal Medicine Malatya Turgut Özal University School of Medicine Malatya Turkey
2. Department of Nephrology İnonu University School of Medicine Malatya Turkey
Abstract
AbstractIntroductionThe prevalence rates of hepatosteatosis and gallstones are increasing owing to the multifactorial causes of chronic kidney disease, and the prevalence may change with the availability of different forms of renal replacement therapy. We aimed to determine the incidence or prevalence rates of hepatosteatosis, cholelithiasis, and acute cholecystitis in patients with chronic kidney disease and compare them between renal replacement therapy modalities.MethodsA total of 270 patients (90 with chronic kidney disease stages III–V, 90 undergoing peritoneal dialysis, and 90 undergoing hemodialysis) were included and categorized into the pre‐dialysis, hemodialysis, and peritoneal dialysis groups. The patients were questioned about previous gallbladder surgeries and chronic diseases. The results of abdominal ultrasonography, tomography, and magnetic resonance imaging were retrospectively evaluated with respect to the findings on the hepatobiliary system. Hepatosteatosis and cholelithiasis were diagnosed by expert radiologists on the basis of abdominal ultrasonography, tomography, and magnetic resonance imaging findings. The prevalence rates of hepatosteatosis, cholelithiasis, and other liver findings were compared between the groups.FindingsHepatosteatosis and cholelithiasis were detected in 16.7% and 21.5% of the 270 cases, respectively. Hepatosteatosis was present in 17.8%, 25.6%, and 6.7% of patients in the pre‐dialysis, hemodialysis, and peritoneal dialysis groups, respectively. The prevalence of hepatosteatosis was significantly higher in patients undergoing hemodialysis than in patients undergoing peritoneal dialysis (p = 0.002). However, no statistically significant difference was found between the peritoneal dialysis and pre‐dialysis groups or between the hemodialysis and pre‐dialysis groups (p >0.05). The prevalence rates of cholelithiasis were 15.6%, 28.9%, and 20.0%, in the pre‐dialysis, hemodialysis, and peritoneal dialysis groups, respectively, and there were no statistically significant differences among the groups. The incidence of acute cholecystitis was significantly higher in the hemodialysis group than in the pre‐dialysis group (p = 0.006).DiscussionOur study showed that the hepatobiliary system is frequently affected in chronic kidney disease and that the findings may differ depending on the renal replacement therapy modality.
Reference32 articles.
1. Gastrointestinal Symptoms in Patients With End-Stage Renal Disease Undergoing Treatment by Hemodialysis or Peritoneal Dialysis
2. Şahinİ.Kronik böbrek yetmezliğinde çölyak hastalığı prevelansı ve çölyak hastalığı saptanan olgularda çölyak hastalığının beslenme parametreleri anemi ve sekonder hiperparatiroidi üzerine etkileri. Yan dal uzmanlık tezi. Yüzüncü Yıl Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Nefroloji Bilim Dalı. Tez Yürütücüsü: Doç.Dr. Reha Erkoç Van.2004.
3. Prevalence of cholelithiasis in a Turkish population of end‐stage renal failure patients and related risk factors: experience of a center from Turkey;Erten S;Turk J Gastroenterol,2008
4. Cholelithiasis: presentation and management;Littlefield A;J MidwiferyWomen's Health,2019
5. Beyond acute cholecystitis—gallstone-related complications and what the emergency radiologist should know